Donepezil HCl & Cognitive Deficits in Autism

Completed · Phase 2 · Has a placebo group

Conditions studied: Autistic Disorder

In brief

This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.

Key facts

Study ID

NCT00047697

Run by

University of Pittsburgh

People needed

34

Starts

2002-10-01

Expected to finish

2006-08-01

Last updated by the study team

2017-10-05

Who can join

Age: 8 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Autism Spectrum Disorder (ASD)
• Asperger's Disorder
• IQ of 75 or above
• Baseline assessment tests within the acceptable range

You may not qualify if…

• Bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder
• Seizure disorder requiring the use of anticonvulsant medications
• Congenital rubella, cytomegalovirus, or tuberous sclerosis
• Certain medications prescribed for management of behavior (please contact the investigator for a complete list)
• Medications/preparations that are known to interact with donepezil HCl
• Significant medical illness, endocrinopathies, cardiovascular disease, or severe chronic malnutrition
• Pregnancy or sexually active females not using a reliable method of contraception

Where it is running

• Western Psychiatric Institute & Clinic — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.